{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:17:58Z","timestamp":1791285478708,"version":"4.1.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Banting and Best Diabetes Centre Postdoctoral fellowship"},{"name":"University of Toronto Department of Medicine Eliot Phillipson Clinician Scientist Training Program"},{"name":"Banting and Best Diabetes Centre Postdoctoral fellowship"},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Research Award"},{"name":"Kidney Foundation of Canada Kidney Research Scientist Core Education and National Training (KRESCENT) Postdoctoral Fellowships"},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Society of Nephrology and CIHR"},{"name":"Clarence Henry Trelford Clinician Scientist Award in Diabetes"},{"name":"Ted Rogers Centre for Heart Research"},{"name":"University of Toronto Provost Post-Doctoral Fellowship Program"},{"name":"Black Research Network and the Canadian Institute for Health Research REDI"},{"name":"Grant"},{"name":"Canadian Heart Function Alliance"},{"name":"Cardiovascular Sciences Collaborative Specialization Queen Elizabeth II\/Heart"},{"name":"Stroke Foundation studentship in Science and Technology"},{"name":"Banting and Best Diabetes Centre-Novo Nordisk studentship"},{"DOI":"10.13039\/100019688","name":"Department of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019688","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Toronto Merit Award"},{"name":"Canadian Institutes of Health Research, Diabetes Canada"},{"name":"Heart & Stroke\/Richard Lewar Centre of Excellence in Cardiovascular Research"},{"name":"CIHR-Kidney Foundation of Canada Team Grant award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>PLAIN ENGLISH SUMMARY<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2009<\/jats:title>\n                    <jats:p>People with chronic kidney disease (CKD) are at a high risk of heart disease and end-stage kidney disease. This review describes how new medications, such as glucagon-like peptide-1 receptor agonists (GLP1RA), aldosterone synthase inhibitors (ASi), soluble guanylate cyclase (sGC) and endothelin receptor antagonists (ERA), can lower heart\u2013kidney risk in people with CKD. GLP1RA are already recommended for managing blood sugar in people with CKD and type 2 diabetes and have been shown to lower the risk of developing end-stage kidney disease. GLP1RA will likely soon be included in clinical guidelines, but further research is needed to understand how these medications protect the kidneys. ASi are another new medication that lower the protein found in urine. Larger trials are being done to see how well these medications work in slowing CKD. Lastly, both sGC agonists and ERAs have been shown to relax blood vessels to improve blood flow in the kidney, and reduce the amount of protein found in urine, both of which are critical to protecting kidneys. Larger clinical trials are being done to see if these medications prevent CKD from getting worse. In summary, this review describes the new and promising treatments for CKD. These therapies hold the potential to slow kidney disease and improve the wellbeing of patients. Further research of these new treatments is important for improving CKD care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ABSTRACT<\/jats:title>\n                    <jats:p>Despite recent advancements in the treatment of chronic kidney disease (CKD), identifying novel therapies beyond guideline-directed therapies that reduce residual cardiorenal risk remains imperative. In this review, we highlight the clinical evidence supporting emerging therapies for CKD, including glucagon-like peptide-1 receptor agonists (GLP1RA) and other incretin-based therapies, aldosterone synthase inhibitors (ASI), endothelin receptor antagonists (ERA), soluble guanylate cyclase (sGC) agonists and anti-inflammatory drugs. Long-acting GLP1RA are already recommended for glycemic control in patients with CKD and type 2 diabetes and the large, dedicated kidney outcome trial FLOW was recently stopped early for efficacy. Emerging clinical trial evidence supports the concept that ASI also provide additional benefit on top of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, which remain a cornerstone of CKD treatment. Next, we consider the use of sGC agonists, which target nitric oxide bioavailability and thereby reduce albuminuria. Finally, we explore the therapeutic potential of ERA, which act through hemodynamic and anti-fibrotic mechanisms, thereby addressing a common final pathway in the development of CKD. Accordingly, our review highlights the changing therapeutic landscape for CKD with promising agents to further prevent the progression of kidney disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfae216","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T08:23:10Z","timestamp":1738743790000},"page":"i47-i58","source":"Crossref","is-referenced-by-count":18,"title":["Upcoming drug targets for kidney protective effects in chronic kidney disease"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-6481","authenticated-orcid":false,"given":"Massimo","family":"Nardone","sequence":"first","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yau","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxcia","family":"Kugathasan","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodele","family":"Odutayo","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Mohsen","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Ouimet","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas S","family":"Sridhar","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z I","family":"Cherney","sequence":"additional","affiliation":[{"name":"University Health Network, Division of Nephrology, Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2025060502163962000_bib1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.00310.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2025060502163962000_bib2","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.1700210.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Writing Group for the CKD Prognosis Consortium","year":"2023","journal-title":"JAMA"},{"key":"2025060502163962000_bib3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ki.2013.44410.1038\/ki.2013.444","article-title":"Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward","volume":"85","author":"Levin","year":"2014","journal-title":"Kidney Int"},{"key":"2025060502163962000_bib4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa01116110.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM19931111329200410.1056\/NEJM199311113292004","article-title":"The Effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-0000710.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"2025060502163962000_bib7","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-810.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2025060502163962000_bib8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab77710.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2025060502163962000_bib9","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.01810.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2025060502163962000_bib10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1053\/j.ackd.2021.04.00210.1053\/j.ackd.2021.04.002","article-title":"Glucagon-like peptide-1 receptor agonists\u2014use in clinical practice","volume":"28","author":"Tric\u00f2","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025060502163962000_bib11","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.ekir.2022.07.16710.1016\/j.ekir.2022.07.167","article-title":"Hemoglobin A1c reduction with the GLP-1 receptor agonist semaglutide is independent of baseline eGFR: post hoc analysis of the SUSTAIN and PIONEER programs","volume":"7","author":"Cherney","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025060502163962000_bib12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-810.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2025060502163962000_bib13","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI7527610.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"key":"2025060502163962000_bib14","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.1293210.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2025060502163962000_bib15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.1428010.1111\/dom.14280","article-title":"The effect of semaglutide 2.4\u00a0mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025060502163962000_bib16","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.10110210.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"2025060502163962000_bib17","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1210\/jc.2013-3809","article-title":"Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease","volume":"99","author":"Idorn","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2025060502163962000_bib18","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1365-2125.2009.03536.x10.1111\/j.1365-2125.2009.03536.x","article-title":"Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide","volume":"68","author":"Jacobsen","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"2025060502163962000_bib19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40262-021-01012-210.1007\/s40262-021-01012-2","article-title":"Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide","volume":"60","author":"Urva","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2025060502163962000_bib20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025060502163962000_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025060502163962000_bib22","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa150922510.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa160382710.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib24","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa160714110.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib25","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa161291710.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-310.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"2025060502163962000_bib27","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa210826910.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-024-00951-7","article-title":"Obesity and the kidney: mechanistic links and therapeutic advances","volume":"20","author":"Yau","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2025060502163962000_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025060502163962000_bib31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S2213-8587(18)30125-6","article-title":"Dulaglutide and renal protection in type 2 diabetes","volume":"6","author":"Cherney","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025060502163962000_bib32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-210.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2025060502163962000_bib33","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z10.1007\/s00125-016-3938-z","article-title":"Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial","volume":"59","author":"Tonneijck","year":"2016","journal-title":"Diabetologia"},{"key":"2025060502163962000_bib34","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2025060502163962000_bib35","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.cjca.2023.07.00710.1016\/j.cjca.2023.07.007","article-title":"Biology and clinical use of glucagon-like-peptide-1 receptor agonists in vascular protection","volume":"39","author":"Yau","year":"2023","journal-title":"Can J Cardiol"},{"key":"2025060502163962000_bib36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-019-0942-x10.1186\/s12933-019-0942-x","article-title":"Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial","volume":"18","author":"Clegg","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2025060502163962000_bib37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.06758410.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"2025060502163962000_bib38","doi-asserted-by":"publisher","first-page":"e140532","DOI":"10.1172\/jci.insight.14053210.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"2025060502163962000_bib39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025060502163962000_bib40","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa230197210.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib41","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-710.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74\u00a0mg with once-weekly semaglutide 2\u00b74\u00a0mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet North Am Ed"},{"key":"2025060502163962000_bib42","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac35210.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"2025060502163962000_bib43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"2025060502163962000_bib44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.03010.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2025060502163962000_bib45","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa202584510.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib46","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa211095610.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-410.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens Res"},{"key":"2025060502163962000_bib48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet North Am Ed"},{"key":"2025060502163962000_bib49","doi-asserted-by":"publisher","first-page":"F671","DOI":"10.1152\/ajprenal.00042.201610.1152\/ajprenal.00042.2016","article-title":"The role of cGMP and its signaling pathways in kidney disease","volume":"311","author":"Shen","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025060502163962000_bib50","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/ki.1996.25610.1038\/ki.1996.256","article-title":"Importance of nitric oxide in the control of renal hemodynamics","volume":"49","author":"Baylis","year":"1996","journal-title":"Kidney Int"},{"key":"2025060502163962000_bib51","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/ijms1906171210.3390\/ijms19061712","article-title":"The impact of the nitric oxide (NO)\/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective","volume":"19","author":"Krishnan","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025060502163962000_bib52","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1161\/CIRCULATIONAHA.108.80029210.1161\/CIRCULATIONAHA.108.800292","article-title":"Cinaciguat (BAY 58\u20132667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure","volume":"119","author":"Lapp","year":"2009","journal-title":"Circulation"},{"key":"2025060502163962000_bib53","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa191592810.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib54","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3390\/jcm908235910.3390\/jcm9082359","article-title":"Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update","volume":"9","author":"Roumeliotis","year":"2020","journal-title":"J Clin Med"},{"key":"2025060502163962000_bib55","doi-asserted-by":"publisher","first-page":"F148","DOI":"10.1152\/ajprenal.00247.201910.1152\/ajprenal.00247.2019","article-title":"Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure","volume":"318","author":"Shea","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025060502163962000_bib56","doi-asserted-by":"publisher","first-page":"e0261000","DOI":"10.1371\/journal.pone.026100010.1371\/journal.pone.0261000","article-title":"Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy","volume":"17","author":"Hu","year":"2022","journal-title":"PLoS One"},{"key":"2025060502163962000_bib57","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1111\/bph.1558610.1111\/bph.15586","article-title":"Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney","volume":"179","author":"Stehle","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2025060502163962000_bib58","doi-asserted-by":"publisher","first-page":"13226","DOI":"10.3390\/ijms24171322610.3390\/ijms241713226","article-title":"The sGC activator runcaciguat has kidney protective effects and prevents a decline of kidney function in ZSF1 rats","volume":"24","author":"Kraehling","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025060502163962000_bib59","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1124\/jpet.122.00142310.1124\/jpet.122.001423","article-title":"The novel, clinical-stage soluble guanylate cyclase activator BI 685509 protects from disease progression in models of renal injury and disease","volume":"384","author":"Reinhart","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"2025060502163962000_bib60","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/cpdd.62710.1002\/cpdd.627","article-title":"A randomized, placebo-controlled, multiple-ascending-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the soluble guanylate cyclase stimulator praliciguat in healthy subjects","volume":"8","author":"Hanrahan","year":"2019","journal-title":"Clin Pharm Drug Dev"},{"key":"2025060502163962000_bib61","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00125-019-05062-x10.1007\/s00125-019-05062-x","article-title":"An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension","volume":"63","author":"Hanrahan","year":"2020","journal-title":"Diabetologia"},{"key":"2025060502163962000_bib62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2215\/CJN.0841052010.2215\/CJN.08410520","article-title":"Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease: a randomized placebo-controlled clinical trial","volume":"16","author":"Hanrahan","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025060502163962000_bib63","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/dom.1509910.1111\/dom.15099","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: a randomized trial","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025060502163962000_bib64","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1681\/ASN.200512125610.1681\/ASN.2005121256","article-title":"The endothelin system and its antagonism in chronic kidney disease","volume":"17","author":"Dhaun","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2025060502163962000_bib65","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/ki.2014.14310.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2025060502163962000_bib66","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1681\/ASN.200906059310.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2025060502163962000_bib67","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1681\/ASN.201008086910.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025060502163962000_bib68","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1681\/ASN.201308083010.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025060502163962000_bib69","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"2025060502163962000_bib70","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.16748610.1161\/HYPERTENSIONAHA.110.167486","article-title":"Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease","volume":"57","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"key":"2025060502163962000_bib71","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-410.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet North Am Ed"},{"key":"2025060502163962000_bib72","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-410.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet North Am Ed"},{"key":"2025060502163962000_bib73","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa230855010.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib74","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41581-019-0234-410.1038\/s41581-019-0234-4","article-title":"Innate immunity in diabetic kidney disease","volume":"16","author":"Tang","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025060502163962000_bib75","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41591-019-0415-510.1038\/s41591-019-0415-5","article-title":"A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes","volume":"25","author":"Niewczas","year":"2019","journal-title":"Nat Med"},{"key":"2025060502163962000_bib76","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12882-022-02794-810.1186\/s12882-022-02794-8","article-title":"Targeting inflammation for the treatment of diabetic kidney disease: a five-compartment mechanistic model","volume":"23","author":"Hofherr","year":"2022","journal-title":"BMC Nephrol"},{"key":"2025060502163962000_bib77","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.kint.2022.10.03010.1016\/j.kint.2022.10.030","article-title":"Targeting inflammation to treat diabetic kidney disease: the road to 2030","volume":"103","author":"Rayego-Mateos","year":"2023","journal-title":"Kidney Int"},{"key":"2025060502163962000_bib78","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa170791410.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2025060502163962000_bib79","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac44410.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur Heart J"},{"key":"2025060502163962000_bib80","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1093\/cvr\/cvab23110.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2025060502163962000_bib81","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.49010.1016\/j.jacc.2018.03.490","article-title":"Inhibition of interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025060502163962000_bib82","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-110.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet North Am Ed"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i47\/61766398\/gfae216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i47\/61766398\/gfae216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T02:16:45Z","timestamp":1749089805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/Supplement_1\/i47\/8002189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":82,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,2,5]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae216","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]}}}